GSK Announcement May Change Industry Speaker Programs

Law360, New York (February 14, 2014, 4:41 PM EST) -- Two common industry practices, paying health care professionals ("HCPs") to speak on a company’s behalf regarding its products to other HCPs and compensating sales professionals based on prescriptions written by HCPs, are receiving close scrutiny these days in response to an announcement from a big industry player.

GlaxoSmithKline PLC announced[1] in December 2013, that it will stop compensating HCPs for speaking on the company’s behalf regarding its products and related disease areas to other HCPs and attendees who potentially could prescribe or influence the prescribing of...
To view the full article, register now.